Pharmaceutical Discovery Corporation

MannKind Corporation, originally founded as Pharmaceutical Discovery Corporation, is a biopharmaceutical company specializing in the development of inhaled therapeutic products for patients with endocrine and orphan lung diseases. The company utilizes its proprietary Technosphere technology, a dry-powder pulmonary delivery platform that allows for rapid absorption of medication into the arterial circulation. Its flagship product, Afrezza, is the only FDA-approved inhaled ultra-rapid-acting insulin for the treatment of type 1 and type 2 diabetes. Additionally, the company developed Tyvaso DPI in partnership with United Therapeutics for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. MannKind continues to expand its pipeline using the Technosphere platform to address high unmet needs in respiratory medicine.